Clinical Trial Update: Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation [Phase 2]

View source ↗

Summary

This Phase 2 safety and efficacy trial of A0001 in patients with the A3243G mitochondrial DNA mutation was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mitochondrial Disease
• Neuromuscular Disease

Drugs mentioned

• A0001

Snippet

Sponsor: Penwest Pharmaceuticals Co. | Conditions: Neuromuscular Disease | Phase 2 | Status: TERMINATED